文献速递湿疹皮炎与荨麻疹

度普利尤单抗联合外用糖皮质激素长期治疗中重度特应性皮炎(LIBERTY AD CHRONOS):一项批判性评价

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a critical appraisal.
PubMed 文献 · Br J Dermatol · 2018-02-27

该多中心随机双盲安慰剂对照试验纳入740例中重度特应性皮炎成人患者,按3:1:3随机接受每周度普利尤单抗300mg、每2周度普利尤单抗300mg或安慰剂,均联合中效外用糖皮质激素至第52周。第16周度普利尤单抗组IGA 0/1和EASI-75达成率均高于安慰剂组,结膜炎、注射部位反应和局部单纯疱疹感染率在度普利尤单抗组更高。

要点

  • 第16周IGA 0/1达成率:每周组39%、每2周组39% vs 安慰剂组12%(P<0.0001)。
  • 第16周EASI-75达成率:每周组64%、每2周组69% vs 安慰剂组23%(P<0.0001)。
  • 度普利尤单抗组结膜炎、注射部位反应和局部单纯疱疹感染率高于安慰剂组。

核心结论

  • 度普利尤单抗联合外用糖皮质激素较单用外用糖皮质激素改善中重度特应性皮炎至第52周,并显示可接受的安全性。

研究设计与样本

  • 多中心随机双盲安慰剂对照试验,在14个国家161个中心开展,纳入740例中重度特应性皮炎成人患者。
  • 按3:1:3随机分配至每周度普利尤单抗300mg联合外用糖皮质激素组319例、每2周度普利尤单抗300mg联合外用糖皮质激素组106例或安慰剂联合外用糖皮质激素组315例,治疗至第52周。
  • 共同主要疗效终点为第16周达到研究者整体评估(IGA)0/1且较基线改善≥2分的患者比例,以及湿疹面积和严重度指数较基线改善75%(EASI-75)的患者比例。

主要发现

  • 第16周IGA 0/1达成率:每周组39%(n=125)、每2周组39%(n=41)vs 安慰剂组12%(n=39),P<0.0001。
  • 第16周EASI-75达成率:每周组64%(n=204)、每2周组69%(n=73)vs 安慰剂组23%(n=73),P<0.0001。
  • 不良事件发生率:每周组261例(83%)、每2周组97例(88%)、安慰剂组266例(84%)。
  • 度普利尤单抗组结膜炎、注射部位反应和局部单纯疱疹感染率高于安慰剂组。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: Blauvelt et al. aimed to compare the long-term efficacy and safety of dupilumab with medium-potency topical corticosteroids (TCS) vs. placebo with TCS in adults with moderate-to-severe atopic dermatitis (AD). SETTING AND DESIGN: This multicentre randomized, double-blinded, placebo-controlled trial was conducted in hospitals, clinics and academic institutions across 161 sites in 14 countries. STUDY EXPOSURE: Adults with moderate-to-severe AD were randomly assigned (3: 1: 3) to receive subcutaneous dupilumab 300 mg once weekly plus TCS, dupilumab 300 mg every 2 weeks plus TCS or placebo plus TCS until week 52. OUTCOMES: Co-primary efficacy end points were percentage of patients achieving Investigator's Global Assessment (IGA) 0/1 and 2 points or higher improvement from baseline, and Eczema Area and Severity Index 75% improvement from baseline (EASI-75) at week 16. RESULTS: In total, 740 patients were included in the trial: 319 were randomly assigned to dupilumab once weekly, 106 to dupilumab every 2 weeks and 315 to the placebo arm. At week 16, more patients in the dupilumab groups achieved the co-primary end points: IGA 0/1 [39% (n = 125) once-weekly dosing, 39% (n = 41) every 2 weeks dosing vs. 12% (n = 39) receiving placebo; P < 0·0001] and EASI-75 [64% (n = 204) and 69% (n = 73) vs. 23% (n = 73); P < 0·0001]. While no new safety signals were identified, adverse effects were noted in 261 (83%) of those receiving dupilumab once weekly plus TCS, 97 (88%) receiving dupilumab every 2 weeks plus TCS and 266 (84%) for those receiving placebo plus TCS. Rates of conjunctivitis, injection site reactions and local herpes simplex infections were higher in the dupilumab groups than in the placebo group. CONCLUSIONS: Blauvelt et al. concluded that dupilumab treatment added to TCS improved AD up to week 52 vs. TCS alone, and also demonstrated acceptable safety.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Thomson J, Wernham AGH, Williams HC, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a critical appraisal. Br J Dermatol. 2018. PMID: 29315479. doi:10.1111/bjd.16317

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。